A NOVEL MODIFIED TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA), E6010, REDUCES REPERFUSION ARRHYTHMIAS INDUCED AFTER CORONARY THROMBOLYSIS - COMPARISON OF NATIVE T-PA AND UROKINASE

The aim of this study was to compare the effects of a novel modified t issue-type plasminogen activator (t-PA), E6010, to those of native t-P A and urokinase on reperfusion arrhythmias (premature ventricular comp lexes: PVC) and the mortality rate after coronary thrombolysis. The fr equency of PVC and the mortality rate were evaluated in anesthetized d ogs which had 1-, 3- or 6-h-old thrombi induced by a copper coil in th e coronary artery. Thrombolytic treatment with a bolus intravenous (iv ) injection of E6010 was compared with the continuous iv administratio n of native t-PA or urokinase. The frequency of PVC was significantly lower in the E6010 group than in the native t-PA and urokinase groups (P<0.05). The mortality rate in the E6010 group (0.0%) tended to be lo wer than those in the native t-PA group (10.7%) and the urokinase grou p (7.1%). These results indicate that the bolus iv injection of E6010 reduced both PVC and the mortality rate, compared with the continuous iv administration of native t-PA or urokinase for coronary thrombolysi s; Therefore, E6010 may have beneficial effects in prehospital thrombo lysis.